<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23208" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperprolactinemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thapa</surname>
            <given-names>Sudan</given-names>
          </name>
          <aff>Louisiana State University, Shreveport</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhusal</surname>
            <given-names>Kamal</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sudan Thapa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamal Bhusal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23208.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>When the amount of serum prolactin exceeds the upper limit, we call it hyperprolactinemia. The common causes of hyperprolactinemia can be physiological, pathological, or drug-induced. Patients with hyperprolactinemia may remain asymptomatic or can present with signs and symptoms of hypogonadism and galactorrhea. This activity reviews the cause and presentation of hyperprolactinemia and stresses the importance of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the causes of hyperprolactinemia.</p></list-item><list-item><p>Describe the evaluation of a patient with hyperprolactinemia.</p></list-item><list-item><p>Summarize the treatment of hyperprolactinemia.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by hyperprolactinemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23208&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23208">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23208.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Prolactin hormone is&#x000a0;exclusively&#x000a0;synthesized&#x000a0;and secreted from lactotrophs&#x000a0;of the anterior pituitary gland. The secretion rate of prolactin is about 200 to 536 mcg/day/meter square<xref ref-type="bibr" rid="article-23208.r1">[1]</xref>&#x000a0;and the half-life is 25 to 50 minutes.&#x000a0;Prolactin&#x000a0;is metabolized&#x000a0;by the&#x000a0;liver (75%) and the kidney (25%). The basal level of prolactin in women averages 13 ng/ml and in men, it averages &#x000a0;5 ng/ml. The upper normal limit of serum prolactin level in most laboratories is 15 to 20 ng/ml. When the amount of serum prolactin exceeds the upper limit, we call it&#x000a0;hyperprolactinemia. The common causes of hyperprolactinemia can be physiological, pathological, or drug-induced. Patients with hyperprolactinemia may remain asymptomatic or can present with signs and symptoms of hypogonadism and galactorrhea.</p>
      </sec>
      <sec id="article-23208.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Physiological, pathological, or pharmacological conditions can cause hyperprolactinemia.<xref ref-type="bibr" rid="article-23208.r2">[2]</xref><xref ref-type="bibr" rid="article-23208.r3">[3]</xref>&#x000a0;Any condition that affects secretion and clearance of prolactin will cause hyperprolactinemia. Physiological hyperprolactinemia is transient and adaptive; whereas, pathological and pharmacological hyperprolactinemia are symptomatic with unwanted&#x000a0;long-term consequences.</p>
        <p>
<bold>Physiological Causes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Nipple stimulation and lactation</p>
          </list-item>
          <list-item>
            <p>Exercise</p>
          </list-item>
          <list-item>
            <p>Stress (hypoglycemia, myocardial infarction, surgery)</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Sleep</p>
          </list-item>
          <list-item>
            <p>Neonatal period</p>
          </list-item>
          <list-item>
            <p>Sexual intercourse</p>
          </list-item>
        </list>
        <p>During pregnancy, the&#x000a0;pituitary gland increases in size, also increasing the size of lactotrophs. The gland may double in size during pregnancy.<xref ref-type="bibr" rid="article-23208.r4">[4]</xref>&#x000a0;Serum prolactin increases throughout the pregnancy and reaches&#x000a0;a peak&#x000a0;at delivery.<xref ref-type="bibr" rid="article-23208.r5">[5]</xref>&#x000a0;It is probably because of increased serum estradiol concentration.&#x000a0;After&#x000a0;delivery, estradiol secretion decreases and the serum prolactin becomes normal with breastfeeding. In pregnancy, serum prolactin usually becomes 10 times normal with a range of 35 to 600 ng/ml at term<xref ref-type="bibr" rid="article-23208.r5">[5]</xref>;&#x000a0;prolactin in amniotic fluid is 100 times more compared to levels in maternal and fetal blood.<xref ref-type="bibr" rid="article-23208.r5">[5]</xref></p>
        <p>Nipple stimulation increases prolactin secretion which&#x000a0;is&#x000a0;mediated&#x000a0;by neural&#x000a0;pathways during breastfeeding. Prolactin secretion increases transiently with suckling reaching up to&#x000a0;300&#x000a0;ng/ml above baseline. The levels increase to 10 ng/ml above baseline in the first week and continue to rise for several months after delivery.<xref ref-type="bibr" rid="article-23208.r5">[5]</xref></p>
        <p><bold>Pathological Causes</bold>&#x000a0;</p>
        <p>
<italic toggle="yes">
<bold>Pituitary Disease</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prolactinoma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acromegaly</p>
          </list-item>
          <list-item>
            <p>Cushing disease</p>
          </list-item>
          <list-item>
            <p>Macroadenoma (compressive)</p>
          </list-item>
          <list-item>
            <p>Plurihormonal adenoma</p>
          </list-item>
          <list-item>
            <p>Lymphocytic hypophysitis</p>
          </list-item>
          <list-item>
            <p>Parasellar mass</p>
          </list-item>
          <list-item>
            <p>Macroprolactinemia&#x000a0;</p>
          </list-item>
        </list>
        <p>Prolactinoma is a benign tumor of lactotrophs. It accounts for up to 40% of all pituitary adenomas. It can present with any level of prolactin elevation from mild elevation to 50,000 ng/ml. In contrast, prolactin elevation from other causes rarely&#x000a0;exceeds 200 ng/ml.<xref ref-type="bibr" rid="article-23208.r6">[6]</xref>&#x000a0;</p>
        <p>
<italic toggle="yes">
<bold>Hypothalamic Disease - Stalk Damage</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tumors like craniopharyngioma, suprasellar pituitary mass extension, meningioma, dysgerminoma, hypothalamic metastases</p>
          </list-item>
          <list-item>
            <p>Granulomas (sarcoidosis, tuberculosis)</p>
          </list-item>
          <list-item>
            <p>Infiltrative disease (histiocytosis disease)</p>
          </list-item>
          <list-item>
            <p>Rathke's cyst</p>
          </list-item>
          <list-item>
            <p>Pituitary stalk&#x000a0;transection (Sellar surgery, head trauma)</p>
          </list-item>
          <list-item>
            <p>Cranial Irradiation</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>Pharmacological Causes</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Estrogen therapy</p>
          </list-item>
          <list-item>
            <p>Thyrotropin-releasing hormone</p>
          </list-item>
          <list-item>
            <p>Antipsychotic/dopamine&#x000a0;receptor blocking agents:&#x000a0; risperidone, haloperidol, fluphenazine, among others</p>
          </list-item>
          <list-item>
            <p>Antiemetic/dopamine receptor blocking agents:&#x000a0;metoclopramide, domperidone, prochlorperazine</p>
          </list-item>
          <list-item>
            <p>Tricyclic antidepressant, selective serotonin receptor inhibitor: amitriptyline, clomipramine, fluoxetine</p>
          </list-item>
          <list-item>
            <p>Anticonvulsant: Phenytoin</p>
          </list-item>
          <list-item>
            <p>Antihypertensive: Verapamil, methyldopa, labetalol</p>
          </list-item>
          <list-item>
            <p>H2 Antihistamines: Cimetidine, ranitidine</p>
          </list-item>
          <list-item>
            <p>Opioid analgesics: Methadone, morphine, apomorphine, heroin</p>
          </list-item>
          <list-item>
            <p>Cholinergic agent: Physostigmine</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>Systemic Disorder</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic renal failure</p>
          </list-item>
          <list-item>
            <p>Polycystic ovarian disease</p>
          </list-item>
          <list-item>
            <p>Liver cirrhosis</p>
          </list-item>
          <list-item>
            <p>Pseudocyesis</p>
          </list-item>
          <list-item>
            <p>Reflex causes: Chest wall trauma, surgery, herpes zoster</p>
          </list-item>
          <list-item>
            <p>Primary hypothyroidism</p>
          </list-item>
        </list>
        <p>
<bold>
<italic toggle="yes">Genetic</italic>
</bold>
</p>
        <p>Inactivating prolactin receptor mutation<xref ref-type="bibr" rid="article-23208.r7">[7]</xref></p>
        <p>
<italic toggle="yes">
<bold>Ectopic Production</bold>
</italic>
</p>
        <p>Bronchogenic carcinoma and hypernephromas<xref ref-type="bibr" rid="article-23208.r8">[8]</xref></p>
        <p>
<italic toggle="yes">
<bold>Idiopathic</bold>
</italic>
</p>
      </sec>
      <sec id="article-23208.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hyperprolactinemia&#x000a0;occurs in less than 1% of the general population and 5% to 14% of patients presenting with secondary amenorrhea.<xref ref-type="bibr" rid="article-23208.r9">[9]</xref>&#x000a0;The most common type is a prolactin-secreting tumor (prolactinoma), accounting for up to 40% of all clinically recognized pituitary adenomas.<xref ref-type="bibr" rid="article-23208.r10">[10]</xref>&#x000a0;The mean prevalence of prolactinoma is estimated to be around 30 per 100,000 in women and 10 per 100,000 in men; with peak prevalence in women aged 25 to 34 years.<xref ref-type="bibr" rid="article-23208.r10">[10]</xref>&#x000a0;Clinical manifestations in women are more obvious and present earlier than in men.</p>
      </sec>
      <sec id="article-23208.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Prolactin is responsible for&#x000a0;milk production during pregnancy and lactation. Along with estrogen, progesterone, possibly insulin-like growth factor-1 (IGF-1), and placental hormones, prolactin stimulates breast alveolar element proliferation in pregnancy.<xref ref-type="bibr" rid="article-23208.r11">[11]</xref>&#x000a0;Lactation is suppressed&#x000a0;during pregnancy due to&#x000a0;the high level of estrogen. Active lactation occurs because of decreased estrogen and progesterone levels and an increase in prolactin levels after delivery. During pregnancy, estrogen has a stimulatory effect on the proliferation of lactotrophs, thereby&#x000a0;secreting prolactin. Lactation results in amenorrhea and secondary infertility because of prolactin-mediated suppression of gonadotropins.</p>
        <p>The hypothalamic control of prolactin secretion is&#x000a0;mostly&#x000a0;inhibitory&#x000a0;by prolactin inhibiting factor&#x000a0;and dopamine is the main inhibitor that acts via type 2 dopamine (D2) receptor<xref ref-type="bibr" rid="article-23208.r12">[12]</xref>&#x000a0;located&#x000a0;on lactotrophs. Thyrotropin-releasing hormone (TRH) is a potent prolactin-releasing factor. There is an elevated&#x000a0;response to both thyroid-stimulating hormone (TSH) and prolactin in primary hypothyroidism. Other prolactin-releasing factors are a vasoactive intestinal peptide (VIP), endothelial growth factor, and dopamine antagonists.</p>
        <p>Drugs like neuroleptics elevate prolactin because of their dopamine receptor&#x000a0;antagonist property, and atypical antipsychotics act by antagonizing both secretions of serotonin and dopamine.</p>
        <p>Pituitary or sellar tumors&#x000a0;inhibit dopamine-induced hyperprolactinemia because of&#x000a0;pressure on the pituitary stalk or interruption of the vascular connections between the pituitary and hypothalamus.</p>
        <p>Prolactin causes inhibition of gonadotropin-releasing hormone (GnRH) leading to&#x000a0;inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.<xref ref-type="bibr" rid="article-23208.r13">[13]</xref> Symptoms of hypogonadism depend upon the magnitude of prolactin elevation.&#x000a0;Serum prolactin greater than 100 ng/dl will have overt hypogonadism with the presentation of amenorrhea, hot flashes, and vaginal dryness. Serum prolactin between 50 to 100 ng/dl may cause amenorrhea or oligomenorrhea and serum prolactin 20 to 50 ng/dl may only shorten the luteal phase because of insufficient progesterone secretion.<xref ref-type="bibr" rid="article-23208.r14">[14]</xref><xref ref-type="bibr" rid="article-23208.r15">[15]</xref></p>
      </sec>
      <sec id="article-23208.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The symptoms of hyperprolactinemia can be due to a direct effect of excess prolactin or the compressive effect of the structural lesion. Hyperprolactinemia causes typical symptoms in premenopausal women and men but not in postmenopausal women.&#x000a0; Reproductive dysfunction and galactorrhea are the hallmarks of hyperprolactinemia. Children and adolescent may have growth arrest, pubertal delay, and primary amenorrhea.</p>
        <p>
<bold>Sign and Symptoms&#x000a0;Caused by High Prolactin</bold>
</p>
        <p>
<bold>
<italic toggle="yes">Women</italic>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Menstrual disturbance: Oligomenorrhea, amenorrhea, menorrhagia or infertility&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Galactorrhea: Most women who have hyperprolactinemia may not have galactorrhea</p>
          </list-item>
          <list-item>
            <p>Low bone mass</p>
          </list-item>
        </list>
        <p>
<bold>
<italic toggle="yes">Men</italic>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypogonadotropic&#x000a0;hypogonadism: Decreased libido, impotence, infertility, oligospermia or gynecomastia&#x000a0;<xref ref-type="bibr" rid="article-23208.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>Erectile dysfunction</p>
          </list-item>
          <list-item>
            <p>Galactorrhea: Rare</p>
          </list-item>
          <list-item>
            <p>Low bone mass</p>
          </list-item>
        </list>
        <p>
<bold>Sign and Symptoms Caused by</bold>
<bold>&#x000a0;Mass Effect&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Visual field defect</p>
          </list-item>
          <list-item>
            <p>External ophthalmoplegic</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23208.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The clinician starts the evaluation of suspected hyperprolactinemia with serum prolactin level, ideally with a fasting mid-morning sample.&#x000a0;An increase in prolactin secretion&#x000a0;is associated with sleep. However, it is not part of the circadian rhythm. The peak level of prolactin is usually between 4 AM and 7 AM. The ideal time to measure prolactin is during the midmorning hours and in the fasting state.&#x000a0;Food has a minimal effect on the serum concentration of prolactin.&#x000a0;So, fasting is not always&#x000a0;an essential condition to measure serum prolactin levels except when&#x000a0;there is a mild elevation on the initial value.</p>
        <p>If serum prolactin is elevated, the next step is to determine the cause in the following order:</p>
        <list list-type="order">
          <list-item>
            <p>Exclusion of physiological causes</p>
          </list-item>
          <list-item>
            <p>Exclusion of pharmacological causes</p>
          </list-item>
          <list-item>
            <p>Neuroradiological imaging of the hypothalamic-pituitary region.</p>
          </list-item>
        </list>
        <p>An extensive history and physical examination are important to exclude causes of hyperprolactinemia and inquire about signs and symptoms of&#x000a0;hyperprolactinemia.</p>
        <p>
<bold>Laboratory Tests</bold>
</p>
        <p>Following tests are generally needed&#x000a0;depending upon gender, age, and clinical presentation:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum prolactin</p>
          </list-item>
          <list-item>
            <p>Thyroid function test</p>
          </list-item>
          <list-item>
            <p>Renal function test</p>
          </list-item>
          <list-item>
            <p>Insulin-like growth factor-1 (IGF-1)</p>
          </list-item>
          <list-item>
            <p>Adrenocorticotrophic hormone (ACTH)</p>
          </list-item>
          <list-item>
            <p>Luteinizing&#x000a0;hormone (LH)</p>
          </list-item>
          <list-item>
            <p>Follicle-stimulating&#x000a0;hormone (FSH)</p>
          </list-item>
          <list-item>
            <p>Testosterone/estradiol</p>
          </list-item>
          <list-item>
            <p>Pregnancy test</p>
          </list-item>
        </list>
        <p>
<bold>Imaging Test</bold>
</p>
        <p>Magnetic&#x000a0;resonance imaging (MRI) of the pituitary with contrast is the preferred imaging study.</p>
        <p>Visual field testing&#x000a0;should be done&#x000a0;in case of macroadenoma and tumor that is adjacent to/or compressing to optic chiasma.</p>
        <p>
<bold>Pitfalls in Diagnosis</bold>
</p>
        <p><italic toggle="yes">Hook Effect:</italic>&#x000a0;It is&#x000a0;because of&#x000a0;an artifact&#x000a0;in the&#x000a0;immunoradiometric&#x000a0;assay giving a falsely low concentration of prolactin.&#x000a0;Hook effect should be kept&#x000a0;in mind with large pituitary adenoma with mild or moderate&#x000a0;elevation in prolactin. When there is&#x000a0;very&#x000a0;high serum prolactin concentration, both the capture and tracer antibodies used in&#x000a0;immunoradiometric&#x000a0;assays become saturated, preventing the binding of the two, to create a sandwich. Then the test result will read low. This&#x000a0;effect can&#x000a0;be&#x000a0;overcome&#x000a0;by repeating the test using a 1:100 dilution of serum.&#x000a0;This artifact is uncommon.</p>
        <p><italic toggle="yes">Macroprolactin</italic>&#x000a0;represents large circulating aggregates of prolactin and antibodies of size about 150&#x000a0;kD; whereas, native prolactin in serum is 23 kD.<xref ref-type="bibr" rid="article-23208.r17">[17]</xref> These complexes are detectable in test assay but are biologically inactive.&#x000a0;They can&#x000a0;be&#x000a0;misdiagnosed as prolactin hypersecretion.&#x000a0;<xref ref-type="bibr" rid="article-23208.r18">[18]</xref>. Clinicians can avoid this misdiagnosis by precipitating&#x000a0;macroprolactin&#x000a0;by&#x000a0;pretreating&#x000a0;with polyethylene glycol before measuring prolactin.</p>
      </sec>
      <sec id="article-23208.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of hyperprolactinemia depends upon the cause. Once the physiological cause of hyperprolactinemia is excluded, we should look for other possible systemic causes and address them for the&#x000a0;symptomatic patient. Here, we are discussing treatment options based on etiology.</p>
        <p>
<bold>Etiology Type</bold>
</p>
        <p>
<italic toggle="yes">
<bold>Hypothyroidism</bold>
</italic>
</p>
        <p>The patient should&#x000a0;be treated with thyroid replacement therapy and confirm the normalization of prolactin level after treatment.</p>
        <p>
<italic toggle="yes">
<bold>Drug-Induced Hyperprolactinemia</bold>
</italic>
</p>
        <p>Treatment is only necessary if patients develop hypogonadism, osteoporosis, or troublesome galactorrhea.<xref ref-type="bibr" rid="article-23208.r19">[19]</xref>&#x000a0;If hyperprolactinemia is suspected&#x000a0;because of drugs, it should&#x000a0;be discontinued&#x000a0;temporarily, if possible, to see if prolactin level normalizes.&#x000a0;If medication cannot&#x000a0;be discontinued,&#x000a0;especially antipsychotics, it should be changed to a different antipsychotics that do not increase prolactin, e.g., quetiapine. If that is not possible, the addition of dopamine agonists should be considered.&#x000a0;These changes should&#x000a0;be made&#x000a0;in consultation with&#x000a0;a psychiatrist. The addition of estradiol in women and testosterone in men can be considered&#x000a0;for hypogonadism and low bone mass.&#x000a0;If prolactin level does not&#x000a0;normalize after stopping meds or if discontinuation of meds is not possible, pituitary MRI should&#x000a0;be done.&#x000a0;</p>
        <p>
<italic toggle="yes">
<bold>Hypothalamic Disease: Stalk Damage</bold>
</italic>
</p>
        <p>Removal of the cause should be the first choice; if not,&#x000a0;hyperprolactinemia should&#x000a0;be treated with the dopamine agonist.</p>
        <p>
<italic toggle="yes">
<bold>Idiopathic Hyperprolactinemia</bold>
</italic>
</p>
        <p>Idiopathic hyperprolactinemia is treated with the&#x000a0;dopamine agonist. However, these patients are relatively resistant to dopamine agonists. Dosage can be adjusted to keep the lowest possible dose with the&#x000a0;normal&#x000a0;level of prolactin. If the patient attains normal prolactin on the&#x000a0;lowest dose of a dopamine agonist for 2 years, the&#x000a0;drug&#x000a0;can be discontinued as a trial.</p>
        <p>
<italic toggle="yes">
<bold>Macroprolactinemia</bold>
</italic>
</p>
        <p>It does not require treatment.</p>
        <p>
<italic toggle="yes">
<bold>Prolactinoma</bold>
</italic>
</p>
        <p>It has medical, surgical, and radiation treatment.</p>
        <p>
<bold>Medical Treatment</bold>
</p>
        <p>Endocrine society guideline recommends against treatment with a dopamine agonist for asymptomatic microadenoma but recommends&#x000a0;dopamine agonist therapy to decrease prolactin levels, tumor size, and normalize gonadal function for symptomatic patients with microadenomas or macroadenomas.&#x000a0;Cabergoline&#x000a0;is preferred&#x000a0;to other dopamine agonists due to&#x000a0;higher efficacy in normalizing prolactin levels&#x000a0;and tumor shrinkage</p>
        <p>Cabergoline&#x000a0;and bromocriptine are commonly used dopamine agonists.&#x000a0;Quinagolide is not available in the United States but used in some other countries. Pergolide&#x000a0;had been withdrawn from the United States because of concern of valvular heart disease. Cabergoline is the first choice because of its efficacy and fewer side effects.<xref ref-type="bibr" rid="article-23208.r20">[20]</xref>&#x000a0;Bromocriptine is preferred&#x000a0;during pregnancy because of more favorable data than cabergoline.<xref ref-type="bibr" rid="article-23208.r10">[10]</xref>&#x000a0;Cabergoline&#x000a0;has a long duration of action than bromocriptine and is administered once or twice a week. Bromocriptine is administered&#x000a0;once daily. Common side effects are nausea, vomiting, nasal stiffness, digital vasospasm, depression, and postural hypotension.&#x000a0;High doses of dopamine agonists are associated with a risk of heart valve regurgitation.<xref ref-type="bibr" rid="article-23208.r21">[21]</xref></p>
        <p>Dopamine agonist&#x000a0;therapy can&#x000a0;be tapered and discontinued after 2 years of continuous therapy if serum prolactin level is normal and no adenoma is visible in magnetic resonance imaging (MRI).</p>
        <p>
<bold>Surgery/Radiation Treatment</bold>
</p>
        <p>Most of the&#x000a0;prolactinomas are treated with medical therapy only. Surgery and radiotherapy&#x000a0;are&#x000a0;reserved for those who are resistant to medical therapy with the&#x000a0;dopamine agonists.&#x000a0;Endoscopic endonasal&#x000a0;transsphenoidal&#x000a0;surgery is the preferred surgical method. Prophylactic surgery is considered&#x000a0;in women with large prolactinoma&#x000a0;which potentially threatens vision during pregnancy.<xref ref-type="bibr" rid="article-23208.r22">[22]</xref> Adjuvant radiation therapy should be considered&#x000a0;for residual tumor. Gamma knife stereotactic radiosurgery is often effective in treating prolactinomas resistant to or intolerant of dopamine agonists.<xref ref-type="bibr" rid="article-23208.r23">[23]</xref></p>
      </sec>
      <sec id="article-23208.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Possible causes of hyperprolactinemia have been mentioned&#x000a0;in the etiology section. In clinical practice, it is important to exclude two important causes of hyperprolactinemia. They are hypothyroidism and the use of drugs that inhibit dopamine.</p>
        <list list-type="bullet">
          <list-item>
            <p>Cirrhosis</p>
          </list-item>
          <list-item>
            <p>Dopamine antagonist medications</p>
          </list-item>
          <list-item>
            <p>Hypothalamic disease</p>
          </list-item>
          <list-item>
            <p>Idiopathic hyperprolactinemia</p>
          </list-item>
          <list-item>
            <p>Pituitary tumors</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Primary hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Prolactinoma</p>
          </list-item>
          <list-item>
            <p>Renal failure</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23208.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Most&#x000a0;patients with micro prolactinomas&#x000a0;have&#x000a0;good prognosis and normalize prolactin levels with treatment. These&#x000a0;patients can be managed&#x000a0;with medical therapy for a&#x000a0;prolonged period. The success of the pituitary surgery also depends upon the size of the tumor, the serum prolactin level, and the experience of the neurosurgeon. The success rate of pituitary surgery is related inversely to tumor size and prolactin levels.<xref ref-type="bibr" rid="article-23208.r24">[24]</xref>&#x000a0;Although&#x000a0;micro prolactinoma surgery has a&#x000a0;high success rate, the recurrence of hyperprolactinemia is relatively&#x000a0;high<xref ref-type="bibr" rid="article-23208.r25">[25]</xref>&#x000a0;which is about 17% in patients initially considered cured. In the case of macroprolactinoma,&#x000a0;around 50% of the patients are in remission after the surgery.&#x000a0;In the case of invasive tumors, complete resection may not be possible, and prolactin normalizes in only 32% of patients with a recurrence rate of about 19%.</p>
      </sec>
      <sec id="article-23208.s11" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Mass effect leading to visual deficits, cranial nerve palsies and pituitary apoplexy</p>
          </list-item>
          <list-item>
            <p>Infertility</p>
          </list-item>
          <list-item>
            <p>Osteoporosis</p>
          </list-item>
          <list-item>
            <p>Blindness</p>
          </list-item>
          <list-item>
            <p>Complications related to cerebrospinal fluid (CSF) leak and hypopituitarism</p>
          </list-item>
          <list-item>
            <p>Hypogonadism</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23208.s12" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>Endocrinologist</p>
          </list-item>
          <list-item>
            <p>Neurosurgeon</p>
          </list-item>
          <list-item>
            <p>Radiation Oncologist</p>
          </list-item>
          <list-item>
            <p>Psychiatrist</p>
          </list-item>
          <list-item>
            <p>Gynecologist</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23208.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Prolactin is one of the hormones secreted by the pituitary gland. Different conditions cause increased secretion of prolactin. The important cause of increased prolactin secretion is a noncancerous&#x000a0;tumor of the pituitary gland called a prolactinoma. It can commonly cause menstrual irregularity, milk secretion from the breast, weak bone, headache, and visual field defects. MRI of the brain may be&#x000a0;required for the evaluation. This can be&#x000a0;treated&#x000a0;successfully with medical therapy alone which normalizes prolactin concentration and also reduces the size of the tumor. In a minority of cases, medication is not effective and should be treated with surgery and rarely with radiation.</p>
      </sec>
      <sec id="article-23208.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The healthcare professionals, acting as an interprofessional team, should educate the patient about the causes of hyperprolactinemia. If they diagnose the patient with prolactinoma, they should counsel the patient on symptoms of a&#x000a0;prolactinoma and when to seek help. There should be effective coordination between endocrinologists and neurosurgeons, and with a psychiatrist, if hyperprolactinemia is the result of the action of dopamine-antagonist drugs. A pharmacist has a role in educating patients on the effectiveness of medication and side effects, and coordinating with the clinicians on drug therapy going forward, including agent selection, dosing, and potential interactions. Oncology nurses should take part to inform the&#x000a0;patient about the possible need for radiation therapy for a large mass and the possibility of hypopituitarism.<xref ref-type="bibr" rid="article-23208.r26">[26]</xref><xref ref-type="bibr" rid="article-23208.r27">[27]</xref></p>
        <p>These interprofessional actions will drive better outcomes in hyperprolactinemia cases. [Level 5]</p>
      </sec>
      <sec id="article-23208.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23208&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23208">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/hyperprolactinemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23208">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23208/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23208">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23208.s16">
        <title>References</title>
        <ref id="article-23208.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ridgway</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Kliman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kjellberg</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Maloof</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Metabolic clearance and production rates of prolactin in man.</article-title>
            <source>J Clin Invest</source>
            <year>1979</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>1669</fpage>
            <page-range>1669-80</page-range>
            <pub-id pub-id-type="pmid">583048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chahal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schlechte</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hyperprolactinemia.</article-title>
            <source>Pituitary</source>
            <year>2008</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-6</page-range>
            <pub-id pub-id-type="pmid">18404389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molitch</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Pathologic hyperprolactinemia.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>877</fpage>
            <page-range>877-901</page-range>
            <pub-id pub-id-type="pmid">1486880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheithauer</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Sano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Randall</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>461</fpage>
            <page-range>461-74</page-range>
            <pub-id pub-id-type="pmid">2159093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guyda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Friesen</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Studies of prolactin secretion in human pregnancy.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>1972</year>
            <month>May</month>
            <day>01</day>
            <volume>113</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-20</page-range>
            <pub-id pub-id-type="pmid">5024994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleinberg</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Noel</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Frantz</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Galactorrhea: a study of 235 cases, including 48 with pituitary tumors.</article-title>
            <source>N Engl J Med</source>
            <year>1977</year>
            <month>Mar</month>
            <day>17</day>
            <volume>296</volume>
            <issue>11</issue>
            <fpage>589</fpage>
            <page-range>589-600</page-range>
            <pub-id pub-id-type="pmid">840242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newey</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gorvin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Willberg</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Bridge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Azharuddin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>van der Merwe</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Klenerman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bountra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thakker</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>Mutant prolactin receptor and familial hyperprolactinemia.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Nov</month>
            <day>21</day>
            <volume>369</volume>
            <issue>21</issue>
            <fpage>2012</fpage>
            <page-range>2012-2020</page-range>
            <pub-id pub-id-type="pmid">24195502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turkington</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Ectopic production of prolactin.</article-title>
            <source>N Engl J Med</source>
            <year>1971</year>
            <month>Dec</month>
            <day>23</day>
            <volume>285</volume>
            <issue>26</issue>
            <fpage>1455</fpage>
            <page-range>1455-8</page-range>
            <pub-id pub-id-type="pmid">5166245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>206</volume>
            <issue>3</issue>
            <fpage>213.e1</fpage>
            <page-range>213.e1-5</page-range>
            <pub-id pub-id-type="pmid">22244474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yatavelli</surname>
                <given-names>RKR</given-names>
              </name>
              <name>
                <surname>Bhusal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Prolactinoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">29083585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richert</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>The insulin-like growth factors (IGF) and IGF type I receptor during postnatal growth of the murine mammary gland: sites of messenger ribonucleic acid expression and potential functions.</article-title>
            <source>Endocrinology</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>140</volume>
            <issue>1</issue>
            <fpage>454</fpage>
            <page-range>454-61</page-range>
            <pub-id pub-id-type="pmid">9886857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horseman</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Montecino-Rodriguez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Engle</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Markoff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dorshkind</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene.</article-title>
            <source>EMBO J</source>
            <year>1997</year>
            <month>Dec</month>
            <day>01</day>
            <volume>16</volume>
            <issue>23</issue>
            <fpage>6926</fpage>
            <page-range>6926-35</page-range>
            <pub-id pub-id-type="pmid">9384572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milenkovi&#x00107;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of gonadotropin hormone-releasing hormone release by prolactin from GT1 neuronal cell lines through prolactin receptors.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1994</year>
            <month>Feb</month>
            <day>15</day>
            <volume>91</volume>
            <issue>4</issue>
            <fpage>1244</fpage>
            <page-range>1244-7</page-range>
            <pub-id pub-id-type="pmid">8108395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sepp&#x000e4;l&#x000e4;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ranta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hirvonen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hyperprolactinaemia and luteal insufficiency.</article-title>
            <source>Lancet</source>
            <year>1976</year>
            <month>Jan</month>
            <day>31</day>
            <volume>1</volume>
            <issue>7953</issue>
            <fpage>229</fpage>
            <page-range>229-30</page-range>
            <pub-id pub-id-type="pmid">55535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corenblum</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pairaudeau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shewchuk</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Prolactin hypersecretion and short luteal phase defects.</article-title>
            <source>Obstet Gynecol</source>
            <year>1976</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>486</fpage>
            <page-range>486-8</page-range>
            <pub-id pub-id-type="pmid">943740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciccarelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guerra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Rosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zarrilli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lombardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Colao</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>PRL secreting adenomas in male patients.</article-title>
            <source>Pituitary</source>
            <year>2005</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-42</page-range>
            <pub-id pub-id-type="pmid">16411067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kavanagh-Wright</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Gibney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>599</fpage>
            <page-range>599-605</page-range>
            <pub-id pub-id-type="pmid">18771565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical relevance of macroprolactin.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>633</fpage>
            <page-range>633-43</page-range>
            <pub-id pub-id-type="pmid">15943822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papakostas</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Klibanski</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>65</volume>
            <issue>12</issue>
            <fpage>1607</fpage>
            <page-range>1607-18; quiz 1590, 1760-1</page-range>
            <pub-id pub-id-type="pmid">15641865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casanueva</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kleinberg</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Montori</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Schlechte</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wass</surname>
                <given-names>JA</given-names>
              </name>
              <collab>Endocrine Society</collab>
            </person-group>
            <article-title>Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>96</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-88</page-range>
            <pub-id pub-id-type="pmid">21296991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antonini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poewe</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.</article-title>
            <source>Lancet Neurol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>826</fpage>
            <page-range>826-9</page-range>
            <pub-id pub-id-type="pmid">17706566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molitch</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy and the hyperprolactinemic woman.</article-title>
            <source>N Engl J Med</source>
            <year>1985</year>
            <month>May</month>
            <day>23</day>
            <volume>312</volume>
            <issue>21</issue>
            <fpage>1364</fpage>
            <page-range>1364-70</page-range>
            <pub-id pub-id-type="pmid">3887166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kondziolka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niranjan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Flickinger</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lunsford</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas.</article-title>
            <source>Pituitary</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>68</fpage>
            <page-range>68-75</page-range>
            <pub-id pub-id-type="pmid">22302560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyrrell</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Lamborn</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Hannegan</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Applebury</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results.</article-title>
            <source>Neurosurgery</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>254</fpage>
            <page-range>254-61; discussion 261-3</page-range>
            <pub-id pub-id-type="pmid">9932878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serri</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rasio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beauregard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Somma</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma.</article-title>
            <source>N Engl J Med</source>
            <year>1983</year>
            <month>Aug</month>
            <day>04</day>
            <volume>309</volume>
            <issue>5</issue>
            <fpage>280</fpage>
            <page-range>280-3</page-range>
            <pub-id pub-id-type="pmid">6866052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langlois</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McCartney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fleseriu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recent Progress in the Medical Therapy of Pituitary Tumors.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-170</page-range>
            <pub-id pub-id-type="pmid">28685507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23208.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cuny</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barlier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feelders</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weryha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Ferone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gatto</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.</article-title>
            <source>Ann Endocrinol (Paris)</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-58</page-range>
            <pub-id pub-id-type="pmid">25556152</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
